Foamix Establishes U.S. Subsidiary And Strengthens Executive Management With Appointment Of Senior U.S. Leadership Team

Foamix Establishes U.S. Subsidiary And Strengthens Executive Management With Appointment Of Senior U.S. Leadership Team

REHOVOT, Israel and BRIDGEWATER, N.J. , June 11, 2014 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals, a clinical-stage, specialty pharmaceutical company focused on the development, patenting and commercialization of proprietary topical foams to address unmet needs in dermatology, today announced the establishment of its U.S. Subsidiary and appointment of five industry veterans in key operational and advisory roles. Dave Domzalski has been appointed President of Foamix Pharmaceuticals Inc., the U.S. subsidiary of Foamix Ltd., Dr. Herman Ellman has been appointed Vice President of Clinical Affairs and Alvin Howard has been appointed Vice President of Regulatory Affairs. Two new external advisors, Carl Reichel and Anthony Bruno, will both serve as Strategic Advisors to management. 

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.